Citations

Clear

2416 citation(s) found for "Yu, Jason L".

A Revised Diagnostic Classification of Canine Glioma: Towards Validation of the Canine Glioma Patient as a Naturally Occurring Preclinical Model for Human Glioma
Koehler, Jennifer W. , Miller, Andrew D. , Miller, C. Ryan , Aldape, Kenneth , Beck, Jessica A. , Corps, Kara N. , Frank, Chad , O’Sullivan, M. Gerard , Rissi, Daniel R. , Simpson, R. Mark , Woolard, Kevin , Shih, Joanna H. , Mazcko, Christina , O’Sullivan, M. Gerard , O'Sullivan, M Gerard , Porter, Brian F. , Brat, Daniel J. , Cornax, Ingrid , Giannini, Caterina , Horbinski, Craig , Huse, Jason T. , Gilbert, Mark R. , LeBlanc, Amy Kathleen

Mayo Clinic

Journal of Neuropathology & Experimental Neurology | September 19, 2018 | Volume: 77 | Issue: 11 | Pages: 1039-1054

10.1093/jnen/nly085 | PMID 30239918 Get It

P05.93 Adult medulloblastoma: analysis of use of chemotherapy in clinical practice
Mastall, Max , Majd, Nazanin , Gule-Monroe, Maria , Khatua, Soumen , Rao, Ganesh , Sandberg, David I. , Zaky, Wafik , Mahajan, Anita , Suki, Dima , Alfaro, Kristin D, Weathers, Shiao‐Pei , Peñas-Prado, Marta , Fuller, Gregory N. , Huse, Jason T. , Wefel, Jeffrey S. , Yeboa, D.N. , Puduvalli, Vinay K. , Harrison, Rebecca A , Groot, John de

Mayo Clinic

Neuro-Oncology | September 19, 2018 | Volume: 20 | Issue: suppl_3 | Pages: iii325-iii325

10.1093/neuonc/noy139.419 Get It

Therapeutic targeting of PFKFB3 with a novel glycolytic inhibitor PFK158 promotes lipophagy and chemosensitivity in gynecologic cancers
Roy, Debarshi , Bhattacharya, Sayantani Sarkar , Jin, Ling, Jung, Deok‐Beom , Kalogera, Eleftheria , Staub, Julie , Wang, Yaxian , X, Wen, Khurana, Ashwani, Chien, Jeremy , Telang, Sucheta , Chesney, Jason , Tapolsky, Gilles , Petras, Dzeja, Shridhar, Viji , Mondal, Susmita, Roy, Debarshi , Sarkar Bhattacharya, Sayantani, Jung, Deokbeom, Xuyang, Wen, Chien, Jeremey , Sarkar Bhattacharya, Sayantani , Mondal, Susmita, Zhang, Song, Xuyang, Wen, Petras, Dzeja

Mayo Clinic

International Journal of Cancer | September 18, 2018 | Volume: 144 | Issue: 1 | Pages: 178-189

10.1002/ijc.31868 | PMID 30226266 Get It

Metabolic alterations are increasingly recognized as important novel anti‐cancer targets. Among several regulators of metabolic alterations, fructose 2,6 bisphosphate (F2,6BP) is a critical glycolytic regulator. Inhibition of the active form of PFKFB3ser461 using a novel inhibitor, PFK158 resulted in reduced glucose uptake, ATP production, lactate release as well as induction of apoptosis in gynecologic cancer cells. Moreover, we found that PFK158 synergizes with carboplatin (CBPt) and paclitaxel (PTX) in the chemoresistant cell lines, C13 and HeyA8MDR but not in their chemosensitive counterparts, OV2008 and HeyA8, respectively. We determined that PFK158‐induced autophagic flux leads to lipophagy resulting in the downregulation of cPLA2, a lipid droplet (LD) associated protein. Immunofluorescence and co‐immunoprecipitation revealed colocalization of p62/SQSTM1 with cPLA2 in HeyA8MDR cells uncovering a novel pathway for the breakdown of LDs promoted by PFK158. Interestingly, treating the cells with the autophagic inhibitor bafilomycin A reversed the PFK158‐mediated synergy and lipophagy in chemoresistant cells. Finally, in a highly metastatic PTX‐resistant in vivo ovarian mouse model, a combination of PFK158 with CBPt significantly reduced tumor weight and ascites and reduced LDs in tumor tissue as seen by immunofluorescence and transmission electron microscopy compared to untreated mice. Since the majority of cancer patients will eventually recur and develop chemoresistance, our results suggest that PFK158 in combination with standard chemotherapy may have a direct clinical role in the treatment of recurrent cancer.
Advances in multidisciplinary therapy for meningiomas
Brastianos, Priscilla K. , Butowski, Nicholas , Chan, Jason W., Dunn, Ian F. , Goldbrunner, Roland , Ippen, Franziska M. , Mawrin, Christian , Sloan, Andrew E. , Snyder, James , Tabatabai, Ghazaleh , Tatagiba, Marcos, Wen, Patrick Y. , Aldape, Kenneth, Nassiri, Farshad , Zadeh, Gelareh , Jenkinson, Michael D. , Raleigh, David R. , Au, Karolyn , Barnhartz-Sloan, Jill, Butowski, N, Carlotti, Carlos Gilberto , Griffith, Brent, Hashizume, Rintaro , Hanemann, C. Oliver , Huang, Raymond Y. , Jungk, Christine, Kaufman, Timothy J, Krischek, Boris , Lee, Ian , Liu, Jeff C. , Mamatjan, Yasin , Mansouri, Alireza , Ng, Ho‐Keung , Pirouzmand, Farhad , Poisson, Laila , Pollo, Bianca , Sahm, Felix , Saladino, Andrea , Santarius, Thomas , Schichor, Christian , Selman, Warren R., Spears, Julian , Suppiah, Suganth , Tatagiba, Marcos, Tirapelli, Daniela, Tsang, Derek S. , Vogelbaum, Michael A. , Deimling, Andreas von , Walbert, Tobias , Westphal, Manfred , Workewych, Adriana M , Tatagiba, Marcos , Galanis, Evanthia , Mansouri, Alireza , von Deimling, Andreas , Sahm, Felix , Huang, Raymond , Lee, Ian Y , Herold‐Mende, Christel C. , McDermott, Michael , Tatagiba, Marcos , Tonn, Joerg-Christian , Wen, Patrick Yung , Bi, Wenya Linda , Cusimano, Michael D. , DiMeco, Francesco , Drummond, Katharine Jann , Giannini, Caterina , Horbinski, Craig , James, David, Jungk, Christine, Lachance, Daniel Honore , Fougère, Christian la , Muñoz, David G. , Noushmehr, Houtan , Perry, Arie , Schultz, David , Schmidt, Nils Ole , Hanemann, C Oliver , Mamatjan, Yasin

Mayo Clinic

Neuro-Oncology | September 17, 2018 | Volume: 21 | Issue: Supplement_1 | Pages: i18-i31

10.1093/neuonc/noy136 | PMID 30649489 Get It

Emergency Physicians' Perceived Influence of EHR Use on Clinical Workflow and Performance Metrics
Denton, Courtney A., Soni, Hiral , Kannampallil, Thomas , Serrichio, Anna, Shapiro, Jason S. , Traub, Stephen J., Patel, Vimla Lodhia

Mayo Clinic

Applied Clinical Informatics | September 12, 2018 | Volume: 09 | Issue: 03 | Pages: 725-733

10.1055/s-0038-1668553 | PMID 30208497 Get It

Objective Over the last decade, electronic health records (EHRs) have shaped clinical practice. In this article, we investigated the perceived effects of EHR use on clinical workflow and meaningful use (MU) performance metrics. Materials and Methods Semistructured interviews were conducted with 20 (n = 20) physicians at two urban emergency departments. Interview questions focused on time spent on EHR use, changes in clinical practices with EHR use, and the effect of MU performance metrics on clinical workflow. Qualitative coding using grounded theory and descriptive analyses were performed to provide descriptive insights. Results Physicians reported that EHRs improved their clinical workflow, especially on MU-related activities including door-to-doctor time and admit decision time. EHR use also affected physicians work efficiency, quality of care provided, and overall patient safety. Conclusion Physicians' perception of EHRs is likely to influence their practices. With negative perceptions of EHR usability problems, positive aspects of EHR use, including the influence on MU performance metrics, may be overridden.
Blood clotting and traumatic injury with shock mediates complement-dependent neutrophil priming for extracellular ROS, ROS-dependent organ injury and coagulopathy
Barrett, Christopher D. , Hsu, Albert, Ellson, Chris D., Miyazawa, Byron , Kong, Y-W, Greenwood, J D, Sperry, Jason L., Park, M S, Cohen, Mitchell J. , Zuckerbraun, Brian S. , Kong, Yi Wen , Kong, Y-W, Dhara, Sanjeev S. , Neal, Matthew D , Yaffe, Michael B.

Mayo Clinic

Clinical and Experimental Immunology | September 9, 2018 | Volume: 194 | Issue: 1 | Pages: 103-117

10.1111/cei.13166 | PMID 30260475 Get It

SummaryPolymorphonuclear (PMN) leucocytes participate in acute inflammatory pathologies such as acute respiratory distress syndrome (ARDS) following traumatic injury and shock, which also activates the coagulation system systemically. Trauma can prime the PMN nicotinamide adenine dinucleotide phosphate (NADPH) oxidase complex for an enhanced respiratory burst, but the relative role of various priming agents in this process remains incompletely understood. We therefore set out to identify mediators of PMN priming during coagulation and trauma-shock and determine whether PMN reactive oxygen species (ROS) generated in this manner could influence organ injury and coagulation. Initial experiments demonstrated that PMN are primed for predominantly extracellular ROS production by products of coagulation, which was abrogated by CD88/C5a receptor(C5aR) inhibition. The importance of this was highlighted further by demonstrating that known PMN priming agents result in fractionally different amounts of extracellular versus intracellular ROS release depending on the agent used. Plasma from trauma patients in haemodynamic shock (n = 10) also primed PMN for extracellular ROS in a C5a-dependent manner, which correlated with both complement alternative pathway activation and thrombin generation. Furthermore, PMN primed by preincubation with products of blood coagulation directly caused loss of endothelial barrier function in vitro that was abrogated by C5aR blockade or NADPH oxidase inhibition. Finally, we show in a murine model of trauma-shock that p47phox knock-out (KO) mice with PMN incapable of generating ROS were protected from inflammatory end-organ injury and activated protein C-mediated coagulopathy. In summary, we demonstrate that trauma-shock and coagulation primes PMN for predominantly extracellular ROS production in a C5a-dependent manner that contributes to endothelial barrier loss and organ injury, and potentially enhances traumatic coagulopathy.
Long-term outcomes of ruxolitinib (RUX) therapy in patients (pts) with myelofibrosis (MF): 5-year update from COMFORT-I.
Catalano, John, Deininger, Michael W. , Miller, Carole B., Silver, Richard T. , Winton, Elliott F., Harvey, Jimmie H., Arcasoy, Murat O. , Lyons, Roger M. , Paquette, Ronald , Raza, Azra , Kornacki, Deanna , Sun, Kang , investigators, COMFORT-I, Gupta, Vikas , Verstovšek, Srđan , Mesa, Ruben A. , Gotlib, Jason , DiPersio, John F. , Talpaz, Moshe , Hexner, Elizabeth O. , Kantarjian, Hagop M. , investigators, COMFORT-I

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 7012-7012

10.1200/jco.2016.34.15_suppl.7012 Get It

HSD3B1 and resistance to androgen deprivation therapy in prostate cancer.
AbuAli, Ghada, Reichard, Chad A. , Chang, Kai‐Hsiung , Carlson, Rachel E. , Rangel, Laureano J. , Reagan, Kevin, Davis, Brian A., Karnes, Jeffrey , Tindall, Donald J., Sharifi, Nima , Hearn, Jason W.D. , Reddy, Chandana A. , Magi‐Galluzzi, Cristina , Davis, Brian, Kohli, Manish , Klein, Eric A.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 5015-5015

10.1200/jco.2016.34.15_suppl.5015 Get It

Safety and efficacy of durvalumab (MEDI4736), a PD-L1 antibody, in urothelial bladder cancer.
Massard, Christophe, Sharma, Sunil, Rafii, Saeed , Colón‐Otero, Gerardo , Hamid, Omid , O’Donnell, Peter H. , Drakaki, Alexandra , Kurland, John F. , Rebelatto, Marlon C., Jin, Xiaoping , Blake-Haskins, John A., Gupta, Ashok , Rafii, Saeed , Gordon, Michael S. , Wainberg, Zev A. , Luke, Jason J. , Curiel, Tyler Jay , Sanborn, Rachel E , Drakaki, Alexandra , Segal, Neil Howard

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 4502-4502

10.1200/jco.2016.34.15_suppl.4502 Get It